---
schema_version: "secwatch.filing_event.v1"
accession: "0001438133-23-000066"
form_type: "8-K"
ticker: "TNDM"
cik: "0001438133"
company_name: "TANDEM DIABETES CARE INC"
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T00:50:12.358083+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tandem Diabetes Q1 revenue $186M, up 14% YoY; net loss $(49.1M)

## Summary
- Revenue $186.0M (+14% YoY); GAAP net loss $(49.1M) or $(0.75) per share.
- Non-GAAP adjusted EBITDA loss $(7.3M) vs $(11.7M) loss a year ago.
- Total pump shipments 37,923, up 5% YoY; U.S. sales $148.7M (+19% YoY).
- International revenue $37.3M, flat YoY; currency headwinds of $4.0M.
- FY 2023 revenue guidance reaffirmed: $790M-$810M; expects gross margin 49-50%.

## SEC filing metadata
- accession: 0001438133-23-000066
- form_type: 8-K
- ticker: TNDM
- cik: 0001438133
- company_name: TANDEM DIABETES CARE INC
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438133/000143813323000066/0001438133-23-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438133/000143813323000066/tndm-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438133-23-000066
- JSON: https://secwatch.observer/filing/0001438133-23-000066.json
- Plain text: https://secwatch.observer/filing/0001438133-23-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.